Corbus Seeking Way Forward In Systemic Sclerosis After Phase III

Results For Placebo On Par With High-Dose Lenabasum

The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations. 

Dominoes
Lenabasum hit a roadblock in systemic sclerosis where results were similar to placebo • Source: Shutterstock

Corbus Pharmaceuticals Holdings, Inc.’s cannabinoid receptor type 2 (CB2) agonist lenabasum – the company’s only clinical-stage drug candidate – failed its first pivotal trial test, but the company is reviewing the data in hopes of finding a way forward for the drug in systemic sclerosis. Corbus said on 8 September that the similar results in the lenabasum and placebo arms of the Phase III clinical trial were due to background immunosuppressive therapy.

The Norwood, MA-based company reported top-line results on 8 September from the RESOLVE-1 trial and said its ongoing analysis of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

More from R&D

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.